EyePoint Pharmaceuticals Appoints Jay S. Duker as the New CEO

EyePoint Pharmaceuticals Appoints Jay S. Duker as the New CEO

July 11, 2023

EyePoint Pharmaceuticals has announced the appointment of Jay S. Duker, M.D. as Chief Executive Officer (CEO). Dr. Duker, previously serving as Chief Operating Officer (COO) and President, has now taken on the CEO role.

Furthermore, Dr. Duker has been added to the Company's Board of Directors, effective immediately. Meanwhile, Nancy S. Lurker has transitioned from the position of CEO to the role of Executive Vice Chair of the Board of Directors.

In 2016, Duker became an independent member of EyePoint's board of directors. He then transitioned to part-time chief strategic scientific officer in 2020 and later assumed the position of full-time chief operating officer in 2021. Earlier this year, Duker took on the role of president.

“I am honored to become chief executive officer of EyePoint at this exciting juncture as we advance our potentially transformational treatment options for a variety of eye diseases and focus on expanding our pipeline by leveraging the sustained delivery capability of our Durasert E technology,” Duker said in the release. “As a physician dedicated to improving outcomes in retinal disease, I am incredibly passionate about EyePoint’s mission of bringing innovative therapies to patients at risk of losing their sight. I look forward to continuing to work with our top-tier executive team and world-class board of directors to build on our recent achievement.”

Lurker, on the other hand, served as EyePoint's CEO for a span of 7 years. During her tenure, she played a pivotal role in advancing EYP-1901 into two phase 2 trials and overseeing the sale of the commercial rights to Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg.

“It has been a privilege to lead the growth of EyePoint into a best- in-class leader in sustained ocular drug delivery, advancing first-in-class therapeutics,” Lurker said in the release. “With the transformation of EyePoint into a pure play drug development company, a compelling clinical pipeline, and recent financial and clinical achievements that put EyePoint in a position of strength, this is the right time to move into a new role. I have never been more excited about our potential and am deeply confident in the company’s future under Jay’s leadership.”

Topics